244 related articles for article (PubMed ID: 36912538)
1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Hamdy FC; Donovan JL; Lane JA; Metcalfe C; Davis M; Turner EL; Martin RM; Young GJ; Walsh EI; Bryant RJ; Bollina P; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Rosario DJ; Rowe E; Mason M; Catto JWF; Peters TJ; Oxley J; Williams NJ; Staffurth J; Neal DE;
N Engl J Med; 2023 Apr; 388(17):1547-1558. PubMed ID: 36912538
[TBL] [Abstract][Full Text] [Related]
2. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
3. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1415-1424. PubMed ID: 27626136
[TBL] [Abstract][Full Text] [Related]
4. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lane JA; Donovan JL; Davis M; Walsh E; Dedman D; Down L; Turner EL; Mason MD; Metcalfe C; Peters TJ; Martin RM; Neal DE; Hamdy FC;
Lancet Oncol; 2014 Sep; 15(10):1109-18. PubMed ID: 25163905
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
6. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
7. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
8. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
Wilt TJ
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
[TBL] [Abstract][Full Text] [Related]
9. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
10. Functional Outcomes After Localized Prostate Cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract][Full Text] [Related]
11. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
[TBL] [Abstract][Full Text] [Related]
12. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C; Magné N; Burban-Provost P; Sargos P; Latorzeff I; Lagrange JL; Supiot S; Belkacemi Y; Peiffert D; Allouache N; Dubray BM; Servagi-Vernat S; Suchaud JP; Crehange G; Guerif S; Brihoum M; Barbier N; Graff-Cailleaud P; Ruffion A; Dussart S; Ferlay C; Chabaud S
Lancet Oncol; 2019 Dec; 20(12):1740-1749. PubMed ID: 31629656
[TBL] [Abstract][Full Text] [Related]
14. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy or watchful waiting in early prostate cancer.
Bill-Axelson A; Holmberg L; Garmo H; Rider JR; Taari K; Busch C; Nordling S; Häggman M; Andersson SO; Spångberg A; Andrén O; Palmgren J; Steineck G; Adami HO; Johansson JE
N Engl J Med; 2014 Mar; 370(10):932-42. PubMed ID: 24597866
[TBL] [Abstract][Full Text] [Related]
16. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
17. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
18. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
Donovan JL; Hamdy FC; Lane JA; Mason M; Metcalfe C; Walsh E; Blazeby JM; Peters TJ; Holding P; Bonnington S; Lennon T; Bradshaw L; Cooper D; Herbert P; Howson J; Jones A; Lyons N; Salter E; Thompson P; Tidball S; Blaikie J; Gray C; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Paul A; Powell P; Prescott S; Rosario DJ; Rowe E; Davis M; Turner EL; Martin RM; Neal DE;
N Engl J Med; 2016 Oct; 375(15):1425-1437. PubMed ID: 27626365
[TBL] [Abstract][Full Text] [Related]
19. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy versus deferred treatment for localised prostate cancer.
Vernooij RW; Lancee M; Cleves A; Dahm P; Bangma CH; Aben KK
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD006590. PubMed ID: 32495338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
